RT Journal Article
T1 Killer-cell immunoglobulin-like receptor expression on lymphocyte subsets in multiple sclerosis patients treated with interferon-β: evaluation as biomarkers for clinical response
A1 García-León, Juan Antonio
A1 López-Gómez, Carlos
A1 Orpez-Zafra, Teresa
A1 Reyes-Garrido, Virginia
A1 Marín Bañasco, Carmen
A1 Oliver-Martos, Begoña
A1 Fernández-Fernández, Óscar
A1 Leyva-Fernández, Laura
K1 Esclerosis múltiple
AB Background: Both the adaptative and the innate immune systems interplay in multiple sclerosis (MS) pathogeny. Killer-cell immunoglobulin-like receptors (KIRs) are key regulators of the immune response, with activating and inhibitory isoforms.Objective: In this study we analysed whether the expression of KIR isoforms is implicated in MS pathogenesis and in the therapeutic response to interferon (IFN)-β.Methods: Peripheral blood samples were collected from 78 IFN-β-treated MS patients and 46 healthy controls (HC). KIR expression was evaluated by flow cytometry on natural killer (NK) and T cells.Results: The expression of KIRs on NK cells and T lymphocytes did not differ between MS patients and HC. IFN-β therapy decreased the expression of KIR2DL1/2DS1 and increased that of KIR2DL2/3 on NK cells. This therapy also reduced KIR2DL1/2DS1, KIR2DL2/2DL3 and KIR3DL2 expression on CD8(+) T cells. The baseline evaluation of the percentage of circulating CD16(+) NK cells was predictive of the clinical response to IFN-β; however, response to this therapy did not appear related to KIR expression.Conclusions: This study shows that expression of KIR isoforms on NK and T lymphocytes correlated in different ways with IFN-β therapy, suggesting that KIR dynamics may be associated with the pathways involved in the mechanisms of action of IFN-β.
PB Springer Link
YR 2014
FD 2014
LK https://hdl.handle.net/10630/33934
UL https://hdl.handle.net/10630/33934
LA eng
NO García-León JA, López-Gómez C, Orpez-Zafra T, Reyes-Garrido V, Marín-Bañasco C, Oliver-Martos B, Fernández O, Leyva L. Killer-cell immunoglobulin-like receptor expression on lymphocyte subsets in multiple sclerosis patients treated with interferon-β: evaluation as biomarkers for clinical response. CNS Drugs. 2014 Jun;28(6):559-70. doi: 10.1007/s40263-014-0153-7. PMID: 24599774.
DS RIUMA. Repositorio Institucional de la Universidad de Málaga
RD 19 ene 2026